Avalon GloboCare (ALBT) Competitors $2.60 -0.20 (-7.14%) Closing price 03:59 PM EasternExtended Trading$2.61 +0.01 (+0.38%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. JATT, IMA, PLUR, BCAB, MDCX, XFOR, MURA, RANI, DYAI, and MRSNShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include JATT Acquisition (JATT), ImageneBio (IMA), Pluri (PLUR), BioAtla (BCAB), Medicus Pharma (MDCX), X4 Pharmaceuticals (XFOR), Mural Oncology (MURA), Rani Therapeutics (RANI), Dyadic International (DYAI), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Its Competitors JATT Acquisition ImageneBio Pluri BioAtla Medicus Pharma X4 Pharmaceuticals Mural Oncology Rani Therapeutics Dyadic International Mersana Therapeutics JATT Acquisition (NYSE:JATT) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation. Does the media refer more to JATT or ALBT? In the previous week, Avalon GloboCare had 2 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for Avalon GloboCare and 1 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.75 beat Avalon GloboCare's score of 0.66 indicating that JATT Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment JATT Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalon GloboCare 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, JATT or ALBT? JATT Acquisition has higher earnings, but lower revenue than Avalon GloboCare. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/AAvalon GloboCare$1.33M7.51-$7.90M-$19.96-0.13 Is JATT or ALBT more profitable? JATT Acquisition has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,451.94%. Avalon GloboCare's return on equity of 0.00% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Avalon GloboCare -1,451.94%N/A -75.12% Do institutionals & insiders hold more shares of JATT or ALBT? 48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 37.3% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryJATT Acquisition beats Avalon GloboCare on 5 of the 9 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.98M$3.11B$5.75B$10.28BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.1321.3674.9926.41Price / Sales7.51240.89456.1088.49Price / CashN/A44.4425.8129.91Price / Book-0.239.6413.256.28Net Income-$7.90M-$53.20M$3.29B$270.38M7 Day Performance10.17%0.41%0.46%2.69%1 Month Performance14.04%4.23%4.59%5.98%1 Year Performance-30.67%9.41%73.41%25.93% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare1.1135 of 5 stars$2.60-7.1%N/A-25.3%$9.98M$1.33M-0.135News CoverageAnalyst DowngradeShort Interest ↑JATTJATT AcquisitionN/A$2.21+0.5%N/A-45.9%$38.12MN/A0.003High Trading VolumeIMAImageneBio3.35 of 5 stars$9.36+0.8%$35.50+279.3%-54.9%$37.63M$9.16M-1.2270Positive NewsGap DownPLURPluri2.7078 of 5 stars$4.77+0.8%$12.00+151.8%-7.7%$37.52M$330K-0.86150Upcoming EarningsGap DownBCABBioAtla2.3515 of 5 stars$0.63+3.6%$5.00+689.9%-57.2%$37.17M$11M-0.5860MDCXMedicus Pharma1.8094 of 5 stars$2.05-2.2%$23.50+1,049.1%N/A$36.44MN/A-1.53N/AGap DownXFORX4 Pharmaceuticals4.6381 of 5 stars$3.18-6.2%$34.17+974.4%-84.7%$36.28M$2.56M-0.2180Positive NewsShort Interest ↓Gap DownMURAMural Oncology2.5393 of 5 stars$2.08+0.2%$12.00+478.3%-36.8%$35.94MN/A-0.24119Short Interest ↑RANIRani Therapeutics3.1934 of 5 stars$0.50-1.0%$7.33+1,381.5%-78.9%$35.58M$1.03M-0.54110Positive NewsShort Interest ↓Gap DownDYAIDyadic International2.5945 of 5 stars$0.98+1.2%$6.00+514.1%-22.0%$35.36M$3.42M-5.147Short Interest ↑MRSNMersana Therapeutics4.0689 of 5 stars$7.02-0.4%$56.60+706.8%-86.5%$35.01M$40.50M-0.48150Positive NewsGap Up Related Companies and Tools Related Companies JATT Acquisition Competitors ImageneBio Competitors Pluri Competitors BioAtla Competitors Medicus Pharma Competitors X4 Pharmaceuticals Competitors Mural Oncology Competitors Rani Therapeutics Competitors Dyadic International Competitors Mersana Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALBT Stock Alerts